Changes after publication

Changes after publication

October 2015: Some changes to recommendation wording were made for clarification only and did not change the meaning of the recommendations. Other changes did alter the meaning. These are indicated by [amended 2015] at the end of the recommendation.

Recommendations that have been changed

Amended recommendation wording (change to meaning)

Recommendation at the time of publication

Recommendation in current guideline

Reason for change

Ensure resources are available to undertake all functions needed as determined by the scope and geographical coverage of the local formulary. (2.3.5)

Take account of the resources needed to undertake all functions of the local formulary decision‑making group, as determined by the scope and geographical coverage of the local formulary. (1.3.5)

The strength of the recommendation has been amended to reflect the need to consider the workload and resources implications of implementing the recommendation locally.

Address barriers that may delay the speed of adoption of medicines into the formulary, such as multiple applications to different decision‑making groups, delayed or absent business planning, budget identification or service design. (2.10.2)

Consider addressing barriers that may delay the speed of adoption of medicines into the formulary, such as multiple applications to different decision‑making groups, delayed or absent business planning, budget identification or service design. (1.10.2)

The strength of the recommendation has been amended to reflect the need to consider the workload and resources implications of implementing the recommendation locally.

Secure adequate training and resources to operate the appeals process. Consider collaborating with neighbouring groups to provide independent cross‑organisational appeals panels. (2.15.6)

Consider collaborating with neighbouring groups to ensure adequate training and resources for the appeals process. This may include providing independent cross‑organisational appeals panels. (1.15.6)

The strength of the recommendation has been amended to reflect the need to consider the workload and resources implications of implementing the recommendation locally.

Changes to recommendation wording for clarification only (no change to meaning)

Recommendation numbers in current guideline

Comment

1.1.3, 1.2.1, 1.2.2, 1.3.3, 1.4.1, 1.5.2, 1.5.3, 1.6.1, 1.6.3, 1.6.4, 1.6.5, 1.6.6, 1.8.1, 1.8.2, 1.9.1, 1.11.1, 1.11.2, 1.12.1, 1.12.2, 1.14.2, 1.14.3, 1.15.2, 1.15.3, 1.15.4, 1.16.1, 1.16.2

Small wording changes have been made for clarification only. There has been no change in meaning.

February 2014: From February 2014, good practice guidance became known as medicines practice guidelines. This is to bring the guideline naming in line with other NICE products. This is purely a name change – the guideline recommendations and everything else remains the same.

August 2013: Recommendation 2.6.1 was amended to provide clarity on the adoption of medicines with a positive NICE technology appraisal into the formulary. The wording 'if clinically appropriate' has been removed from the recommendation.

The Department of Health has published several documents to support the adoption of NICE technologies onto local formularies, including The NHS Constitution, the 'Comply or Explain' regime (as part of Everyone counts: Planning for patients 2013/14) and Innovation, Health and Wealth: Accelerating Adoption and Diffusion in the NHS (2011, updated 2012). The change in wording is to avoid any misinterpretation of the recommendation.

ISBN: 978-1-4731-1477-7

  • National Institute for Health and Care Excellence (NICE)